QUICK ANSWER · AEO / GEO
YK-11 is an experimental steroidal androgen-receptor partial agonist commonly placed in the SARM class; it is not follistatin, a myostatin-neutralising biologic or testosterone. The frequently cited follistatin finding comes from mouse C2C12 cells, not a human efficacy trial. Rat research reported neurochemical and memory-related changes. FDA states that no SARM is approved and discusses a stroke report involving a tested YK-11-labelled product, without proving universal product identity or sole causation. WADA prohibits YK-11 at all times.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
- C2C12 follistatin expression ≠ human myostatin treatment; animal neurochemistry ≠ quantified human risk; product-associated report ≠ proof that one compound alone caused every outcome
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
FAQ · ANSWER ENGINE
Frequently asked questions
What is YK-11?
YK-11 is described pharmacologically as Experimental steroidal androgen-receptor partial agonist / SARM-class candidate. YK-11 is an experimental steroidal androgen-receptor partial agonist commonly placed in the SARM class; it is not follistatin, a myostatin-neutralising biologic or testosterone. The frequently cited follistatin finding comes from mouse C2C12 cells, not a human efficacy trial. Rat research reported neurochemical and memory-related changes. FDA states that no SARM is approved and discusses a stroke report involving a tested YK-11-labelled product, without proving universal product identity or sole causation. WADA prohibits YK-11 at all times.
Does YK-11 have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is YK-11 approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.